JUXTAPID

This brand name is authorized in Canada, Japan, United States

Active ingredients

The drug JUXTAPID contains one active pharmaceutical ingredient (API):

1 Lomitapide UNII X4S83CP54E - LOMITAPIDE MESYLATE

Lomitapide directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL. The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C. Read about Lomitapide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JUXTAPID Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AX12		C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02420341, 02420376, 02420384
Country: JP	医薬品医療機器総合機構	Identifier(s): 2189020M1023, 2189020M2020, 2189020M3026
Country: US	FDA, National Drug Code	Identifier(s): 76431-105, 76431-110, 76431-120, 76431-130